Welcome to our dedicated page for Exelixis SEC filings (Ticker: EXEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Exelixis Inc. filings document regulatory disclosures for a Nasdaq-listed oncology company with common stock trading under EXEL. Recent 8-K reports furnish results of operations, financial-condition updates, corporate updates tied to the cabozantinib franchise and pipeline activity, and board-authorized common stock repurchase programs.
Proxy and governance filings cover director election matters, executive compensation, equity awards and shareholder voting materials. Other current reports document officer appointments, departures and related compensatory arrangements, connecting leadership changes to the company's research, development, legal and corporate functions.
EXELIXIS, INC. director Jack L. Wyszomierski reported an open-market sale of 3,925 shares of common stock at $50.55 per share. The transaction was executed on June 1, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. Following this sale, he directly holds 284,384 shares of Exelixis common stock, and the filing notes an additional 8,367 shares that will be delivered upon vesting of restricted stock units.
EXELIXIS, INC. director Sue Gail Eckhardt reported an open-market sale of 9,812 shares of Common Stock at a weighted average price of $50.14 per share on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025.
After this transaction, her reported holdings total 16,079 shares of Common Stock, including shares that will be issued upon vesting of restricted stock units, with each unit economically equivalent to one share.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Stelios Papadopoulos received an equity award in the form of 8,367 restricted stock units, each equivalent to one share of common stock. The grant was made at no cash cost to him.
The RSUs are scheduled to vest 100% on May 27, 2027, provided he remains in continuous service through that date. After this award, his direct holdings reported in this filing total 1,197,595 shares of common stock, including the shares underlying the RSUs.
Heyman Tomas J. reported acquisition or exercise transactions in this Form 4 filing.
Exelixis director Tomas J. Heyman received a new equity award. He was granted 8,367 restricted stock units (RSUs) of Exelixis common stock on May 27, 2026 under the 2017 Equity Incentive Plan, with no cash paid per share.
Each RSU equals one share of common stock and will vest 100% on May 27, 2027, if he continues serving through that date. After this grant, Heyman holds 50,649 shares in total, including 17,455 shares that will be issued when previously granted RSUs vest.
Eckhardt Sue Gail reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Sue Gail Eckhardt received a grant of 8,367 restricted stock units on May 27, 2026 under the company’s 2017 Equity Incentive Plan. Each RSU represents one share of common stock and will vest in full on May 27, 2027 if she remains in continuous service. Following this award, she holds 25,891 shares of common stock, including 16,079 shares that will be issued upon vesting of outstanding RSUs.
Smith Julie reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Julie Smith reported an equity compensation grant of 8,367 restricted stock units on May 27, 2026. The award carries no purchase price and each unit is economically equivalent to one share of common stock.
The RSUs will vest in full on May 27, 2027, provided she remains in continuous service through that date. Following this grant, Smith is shown as holding 28,957 shares of common stock, including the shares that will be issued upon vesting of these RSUs.
Freire Maria C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Maria C. Freire received a grant of 8,367 restricted stock units (RSUs) on May 27, 2026 under the Exelixis, Inc. 2017 Equity Incentive Plan. Each RSU equals one share of common stock and will vest 100% on May 27, 2027, subject to her continuous service. After this award, she directly holds 109,186 shares of common stock, including the shares underlying these RSUs.
Beckerle Mary C reported acquisition or exercise transactions in this Form 4 filing.
EXELIXIS, INC. director Mary C. Beckerle received a grant of 8,367 restricted stock units (RSUs), each equal to one share of common stock. The award was granted under the 2017 Equity Incentive Plan and will vest in full on May 27, 2027, subject to continuous service. Following this grant, she holds 25,891 shares and RSUs, including 16,079 shares issuable upon future RSU vesting.